Philip Morris $PM (+0,34 %) has permission to market 20 ZYN products (2 strengths per 10 flavors).
The FDA's decision sets the stage for further marketing of Reduced Risk Products.
I hope, however, that the FDA will pay close attention to who they give permission to and that the barriers to market entry will remain high.
